[Heptral potentialities in the treatment of hepatic damage in children with malignant blood disease].
OBJECTIVE
To assess benefit for children with malignant blood disease (MBD) of the hepatoprotector heptral.


METHODS
67 children with blood malignancy aged 3-14 years were examined (53 of them had acute lymphoblastic leukemia). 39 patients were in the study group (25 of them had hepatitis B or C), 28 were controls. Initially, heptral was injected intravenously (14 days) then orally (16-30 days). Activity of transaminases and number of violations of polychemotherapy protocols because of hepatic toxicity were registered.


RESULTS
Heptral administration led to inhibited activity of AlAT and AsAT especially in non-infected patients. Protocol deviations became less frequent.


CONCLUSIONS
Heptral is a potent hepatoprotector in hepatic lesions of toxic, viral and mixed origin.
Reĭzis
A R
AR
Nurmukhametova
E A
EA
D000293:Adolescent; D000410:Alanine Transaminase / Q000097:blood*; D000970:Antineoplastic Agents / Q000009:adverse effects; D001219:Aspartate Aminotransferases / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D002648:Child; D002675:Child, Preschool; D004333:Drug Administration Routes; D005500:Follow-Up Studies; D019337:Hematologic Neoplasms / Q000150:complications* / Q000188:drug therapy / Q000201:enzymology; D006801:Humans; D008107:Liver Diseases / Q000150:complications / Q000188:drug therapy* / Q000201:enzymology; D008297:Male; D012189:Retrospective Studies; D012436:S-Adenosylmethionine / Q000008:administration & dosage / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D015415:Biomarkers; D012436:S-Adenosylmethionine; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase
Vozmozhnosti i perspektivy primeneniia geptrala pri lechenii porazheniia pecheni u deteĭ s onkogematologicheskimi zabolevaniiami.